-
Je něco špatně v tomto záznamu ?
Gene Editing and Human iPSCs in Cardiovascular and Metabolic Diseases
S. Giallongo, O. Lo Re, I. Resnick, M. Raffaele, M. Vinciguerra
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- diabetes mellitus 2. typu * genetika terapie MeSH
- editace genu MeSH
- indukované pluripotentní kmenové buňky * MeSH
- kardiovaskulární systém * MeSH
- lidé MeSH
- metabolické nemoci * genetika terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The incidence and the burden of cardiovascular disease (CVD), coronary heart disease (CHD), type 2 diabetes mellitus (T2DM), and the metabolic syndrome are greatly increasing in our societies. Together, they account for 31% of all deaths worldwide. This chapter focuses on the role of two revolutionary discoveries that are changing the future of medicine, induced pluripotent stem cells (iPSCs) and CRISPR/Cas9 technology, in the study, and the cure of cardiovascular and metabolic diseases.We summarize the state-of-the-art knowledge about the possibility of editing iPSC genome for therapeutic applications without hampering their pluripotency and differentiation, using CRISPR/Cas technology, in the field of cardiovascular and metabolic diseases.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032007
- 003
- CZ-PrNML
- 005
- 20230131150629.0
- 007
- ta
- 008
- 230120s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/978-981-19-5642-3_18 $2 doi
- 035 __
- $a (PubMed)36454473
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Giallongo, Sebastiano $u Epigenetics, Metabolism and Aging Unit, Center for Translational Medicine, International Clinical Research Center, St'Anne University Hospital, Brno, Czech Republic
- 245 10
- $a Gene Editing and Human iPSCs in Cardiovascular and Metabolic Diseases / $c S. Giallongo, O. Lo Re, I. Resnick, M. Raffaele, M. Vinciguerra
- 520 9_
- $a The incidence and the burden of cardiovascular disease (CVD), coronary heart disease (CHD), type 2 diabetes mellitus (T2DM), and the metabolic syndrome are greatly increasing in our societies. Together, they account for 31% of all deaths worldwide. This chapter focuses on the role of two revolutionary discoveries that are changing the future of medicine, induced pluripotent stem cells (iPSCs) and CRISPR/Cas9 technology, in the study, and the cure of cardiovascular and metabolic diseases.We summarize the state-of-the-art knowledge about the possibility of editing iPSC genome for therapeutic applications without hampering their pluripotency and differentiation, using CRISPR/Cas technology, in the field of cardiovascular and metabolic diseases.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a indukované pluripotentní kmenové buňky $7 D057026
- 650 _2
- $a editace genu $7 D000072669
- 650 12
- $a diabetes mellitus 2. typu $x genetika $x terapie $7 D003924
- 650 12
- $a kardiovaskulární systém $7 D002319
- 650 12
- $a metabolické nemoci $x genetika $x terapie $7 D008659
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lo Re, Oriana $u Epigenetics, Metabolism and Aging Unit, Center for Translational Medicine, International Clinical Research Center, St'Anne University Hospital, Brno, Czech Republic $u Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University - Varna, Varna, Bulgaria
- 700 1_
- $a Resnick, Igor $u Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University - Varna, Varna, Bulgaria $u Department of Hematology, Bone Marrow Transplantation and Cell Therapy of St. Marina University Hospital, Varna, Bulgaria
- 700 1_
- $a Raffaele, Marco $u Epigenetics, Metabolism and Aging Unit, Center for Translational Medicine, International Clinical Research Center, St'Anne University Hospital, Brno, Czech Republic
- 700 1_
- $a Vinciguerra, Manlio $u Epigenetics, Metabolism and Aging Unit, Center for Translational Medicine, International Clinical Research Center, St'Anne University Hospital, Brno, Czech Republic. manliovinciguerra@gmail.com $u Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University - Varna, Varna, Bulgaria. manliovinciguerra@gmail.com $u Liverpool Centre for Cardiovascular Science (LCCS), Liverpool John Moores University (LJMU), Liverpool, United Kingdom. manliovinciguerra@gmail.com
- 773 0_
- $w MED00008501 $t Advances in experimental medicine and biology $x 0065-2598 $g Roč. 1396, č. - (2023), s. 275-298
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36454473 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150626 $b ABA008
- 999 __
- $a ok $b bmc $g 1891032 $s 1183342
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 1396 $c - $d 275-298 $e - $i 0065-2598 $m Advances in experimental medicine and biology $n Adv Exp Med Biol $x MED00008501
- LZP __
- $a Pubmed-20230120
